Skip to content

Chris Seeger Appointed to the Humira MDL Executive Committee

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira. A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the […]

June 7, 2019

Chris Seeger headshot

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira.

A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the companies engaged in unfair competitive acts regarding Humira and its related patents. These cases have been consolidated into multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois under Judge Manish S. Shah.

Judge Shah has appointed Seeger Weiss founding partner, Chris Seeger to the Executive Committee for the Humira MDL. The MDL Executive Committee is comprised of nine attorneys which includes three co-lead counsels from New York, California and Massachusetts and six plaintiff’s executive committee members from Louisiana, New York, Pennsylvania, and California.

The lawsuits claim that AbbVie engaged in improper anti-competitive action to protect its market exclusivity of autoimmune drug Humira. The lawsuits have been brought by insurance and managed care payers who may have been improperly forced to pay higher costs for Humira versus similar medications which were blocked from the U.S. market.

Humira is a flagship drug of AbbVie and brings the company over $20 billion per year in revenue. It is used for a number of autoimmune disorders including Rheumatoid Arthritis and is the best-selling medication of its type. Outside of the U.S., Humira faces competition from biosimilar medications but AbbVie has been successful in preventing U.S. competition with a web of over 100 patents that surround the medication.

Related News

December 1, 2022
Seeger Weiss now accepting applicants for 2023 Diversity Fellowship

Seeger Weiss LLP announced today that the application period for the firm’s 2023 Diversity Fellowship is now open. Seeger Weiss is committed to providing an inclusive, equitable workplace where team members from all backgrounds can thrive and grow. We believe that diversity makes workplaces, institutions, and our world stronger, smarter, more resilient, and more just. […]

Read More
November 11, 2022
Chris Seeger appointed co-lead counsel in In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation

Seeger Weiss is proud to announce founder Chris Seeger has been appointed to serve as co-lead counsel in the In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation by the honorable Judge Yvonne Gonzalez Rogers. Seeger was one of three lawyers selected to lead the multidistrict litigation pending in the Northern District of California, […]

Read More
November 4, 2022
Seeger Weiss founding partner Chris Seeger helps negotiate $10 billion agreements with Walgreens and CVS in National Prescription Opiate Litigation

Seeger Weiss founding partner Chris Seeger along with partner Jennifer Scullion helped lead the National Prescription Opiate Litigation team in negotiations with Walgreens and CVS that culminated in over $10 billion in settlement agreements to help communities across the country ravaged by the opioid epidemic. In addition to Seeger and Scullion, negotiations were led by […]

Read More